Price$31.94-0.32 (-0.99%)
01:30 PM07:45 PM
News · 26 weeks45-33%
2025-10-262026-04-19
Mix2590d
- SEC Filings17(68%)
- Other8(32%)
Latest news
25 items- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRNew data for Smith+Nephew's CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant demonstrates superior pain relief and functional gains at 5-yearsSmith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces further compelling evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its CARTIHEAL AGILI-C Cartilage Repair Implant recently published in the American Journal of Sports Medicine (AJSM). The CARTIHEAL AGILI-C Cartilage Repair Implant resulted in higher overall Knee injury and Osteoarthritis Outcome Scores (KOOS) versus surgical standard of care* for all time points out to 60 months.1,2 Superior pain relief: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 5-year perio
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECAmendment: SEC Form 6-K/A filed by Smith & Nephew SNATS Inc.6-K/A - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew's REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*Results from the first-ever randomized control trial for the REGENETEN Implant in partial-thickness rotator cuff repair Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces compelling new randomized control trial (RCT) data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the REGENETEN Bioinductive Implant in isolation.1,* Compared with a traditional suture anchor repair, early recovery time was halved1 for patients returning to daily activities such as: Driving: 2.3 vs 5.1 weeks (p<0.001)1,**Office work: 1.7 vs 3.6 weeks (p=0.009)1,**Moderate-intensity household chores: 3.8 vs 8.4 weeks (p<
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 20-F filed by Smith & Nephew SNATS Inc.20-F - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury preventionSmith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, recently announced the launch of ALLEVYN♢ COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed by a portfolio of strong scientific data and clinical evidence. ALLEVYN COMPLETE CARE Dressing has a unique five-layer construction with distinct mode of action technologies targeted towards both wound management and pressure injury prevention. Minimising leakage1-4 and disruption by fewer dressing changes5-7, and protecting vulnerable skin8-10 are essential to achieving this goal. Global estimates suggest that up to one in 50 adults are affected by chronic wounds in their lifetime, facing
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature handheld robotics and digital solutions for hip, knee and shoulder in addition to innovative trauma and extremities products during the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans this week. Some of the company's latest Orthopaedics advancements and highlighted technologies include:Handheld Robotics: Optimizing and Personalizing Surgery As the leader in handheld robotics, the CORI◊ Surgical System delivers a digital surgery ecosystem–spanning solutions from advanced pre-operative planning and a connected post-operative data management solution. The entir
- PRSmith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026Uniting the most advanced technologies for biomechanical repair and biological augmentation Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase its unrivalled portfolio for rotator cuff repair (RCR) during the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans this week. RCR is a growing market segment with approximately 500,000 procedures performed annually in the US,1 yet still experiencing 20–40%2 structural failure rates using traditional surgical techniques. Tendon Seam offers a new and unique biomechanical repair technique alongside market-leading biological augmentation of the REGENETEN Bioinducti
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC™) to our surgeonsSmith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed an exclusive US distribution agreement with RMR Ortho to add the A'TOMIC™ Nitinol Fixation System to the Smith+Nephew Trauma, Foot & Ankle and Hand & Wrist portfolio. The system is designed to improve implant integrity and patient comfort1-6—key priorities for surgeons and healthcare systems alike."This partnership with RMR Ortho strengthens Smith+Nephew's fixation portfolio by adding a dynamic compression fixation solution that complements our existing technologies," said Scott Gunn, Vice President of U.S. Marketing, Trauma, Extremities, and Shoulder at Smith+Nephew. "The A'TOMIC Nitinol F
- PRSmith+Nephew signs distribution agreement with SI-BONETrauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announced it has signed a distribution agreement with SI-BONE, focused on their innovative iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and strengthens our position in high-frequency, high-impact trauma procedures."We're incredibly excited to partner with SI-BONE," said Scott Gunn, Vice President Trauma, Extremities and Shoulder. "This collaboration reflects a share
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)